The latest V3.2022 NCCN guidance for CML requires that, before TKI discontinuation, patients be over 18 years old in the CML‐CP, with no prior history of accelerated or blast phase CML, and have quantifiable BCR::ABL1 transcripts.14 This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.